Abstract
Background/Objectives:
Phenylketonuria (PKU) and several other inherited metabolic diseases (IMD) require a lifelong low-protein diet (LPD), otherwise they lead to many health complications. LPDs, however, carry a significant economic burden for patients and their families. The objective of this study was to explore the costs of low-protein foods (LPFs) necessary for LPD as well as dietary patterns and compliance towards an LPD.
Subjects/Methods:
A detailed questionnaire was created in cooperation with National Association of PKU and other IMD (NSPKU), and consequently sent to all NSPKU members treated with an LPD (n=303). A total of 184 respondents from the Czech Republic were included in the study (174 had PKU, 10 had other IMD).
Results:
The average daily consumption of LPF was equal to 411.7 g (PKU) and 345.6 g (other IMD), which corresponds to energy value of 5558 kJ and 4438 kJ, respectively, per patient per day. Patients mostly consumed low-protein flour (≈30% of energy intake), pasta (≈18%), basic pastry (≈15%) and sweets (≈10%). The average monthly costs of LPDs were equal to €130 (PKU) and €129 (other IMD) per patient per month. The compliance with LPD was decreasing with increasing age (P<0.0001).
Conclusions:
This is the largest study examining costs and dietary patterns of LPDs in patients with PKU and the first study of this kind in other IMD patients requiring an LPD. The study clearly showed that an LPD carries a very high economic burden for families, which may lead to less LPD compliance and potential severe health consequences.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Blau N, Spronsen JFv, Levy LH . Phenylketonuria. Lancet 2010; 376: 1417–1427.
Honzík T, Zeman J (2013). Dědičné metabolické poruchy v dětském věku, Institut postgraduálního vzdělávání ve zdravotnictví. Available at http://www.vzdelavani-zdravotniku.cz/autorska-dila/lekari/dedicne_poruchy%20metabolismu/dedicne_poruchy%20metabolismu.html (accessed 27 September 2016).
Neonatal screening in the Czech Republic. The actual epidemiological statistics and the complete list of IMD included in the screening. Available at http://www.novorozeneckyscreening.cz/vysledky-ns-2012-19-10-2015-131436; http://www.novorozeneckyscreening.cz/ov-co-je-novorozenecky-screening (accessed 27 September 2016).
Orphanet, the portal for rare disease. Available at http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=173&Disease_Disease_Search_diseaseGroup=homocystinuria&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Classic-homocystinuria&title=Classic-homocystinuria&search=Disease_Search_Simple (accessed 27 September 2016).
Pampols T . Inherited metabolic rare disease in rare disease epidemiology. Adv Exp Med Biol 2010; 686: 397–431.
Camp MK, Parisi AM, Acosta PB, Berry TG, Bilder AD, Blau N et al. Phenylketonuria scientific research review konference: state of the science and future research needs. Mol Genet Metab 2014; 112: 87–122.
Hagedorn ST, Berkel P, Hammerschmidt G, Lhotakova M, Saludes PR . Requirements for a minimum standard of care for phenylketonuria: the patients’ perspective. Orphanet J Rare Dis 2013; 8: 191.
Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007; 92: 63–70.
Bone A, Kuehl KA, Angelino FA . A neuropsychiatric perspective of phenylketonuria I: overview of phenylketonuria and its neuropsychiatric sequelae. Psychosomatics 2012; 53: 517–523.
Modan-Moses D, Vered I, Schwarz G, Anikster Y, Abraham S, Segev R et al. Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 2007; 30: 202–208.
Fisch RO, Chang PN, Weisberg S, Guldbert P, Guttler F, Tsai MY . Phenylketonuric patients decades after diet. J Inherit Metab Dis 1995; 18: 347–353.
Koch R, Azen C, Friedman EG, Fishler K, Baumann-Frischling C, Lin T . Care of the adult with pnhenylketonuria. Eur J Pediatr 1996; 155: S90–S92.
Leuzzi V, Pansini M, Sechi E, Chiarotti F, Carducci C, Levi G et al. Executive function impairment in early-treated PKU subjects with normal mental development. J Inherit Metab Dis 2004; 27: 115–125.
Burgard P . Development of intelligence in early treated phenylketonuria. Eur J Pediatr 2000; 159: S74–S79.
Cleary M, Trefz F, Muntau AC, Feillet F, Spronsen JF, Burlina A et al. Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes. Mol Genet Metab 2013; 110: 418–423.
Morris AMA, Kožich V, Santra S, Andria G, Ben-Omran MIT, Chakrapani BA et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 2017; 40: 49–74.
Baumgartner RM, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman AK et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis 2014; 9: 130.
Frazier MD, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F et al. Nutrition management guidelines for maple syrup urine disease: an evidence- and concensus-based approach. Mol Genet Metab 2014; 112: 210–217.
Laet de C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 2013; 8: 8.
Urea Cycle Treatment Guidelines. Rare Diseases Clinical Research Network. Available at http://www.rarediseasesnetwork.org/cms/ucdc/Healthcare-Professionals/Urea-Cycle-Treatment-Guidelines (accessed 27 September 2016).
Blau N, Spronsen JF, Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Blau N et al. (eds). Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Disease. Springer-Verlag: Berlin Heidelberg, 2014.
Pena MJ, Almeida MF, Dam E, Ahring K, Belanger-Quintana, Dokoupil K et al. Protein substitutes for phenylketonuria in Europe: access and nutritional composition. Eur J Clin Nutr 2016 70: 785–789.
Eijgelshoven I, Demirdas S, Smith TA, Jeanni MTL, Latour S, Bosch AM . The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands. Mol Genet Metab 2013; 109: 237–242.
Belanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeldt K et al. Diet in phenylketonuria: a snapshot of special dietary costs and reimbursement systems in 10 international centers. Mol Genet Metab 2012; 105: 390–394.
Wang L, Zou H, Ye F, Wang K, Li X, Chen Z et al. Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study. J Inherit Metab Dis; 40: 369–376.
Honzík T, Zeman J, Kožich V (2014). Dědičné poruchy metabolismu in Kateřina Kubáčková a kol., Vzácná onemocnění v kostce, Mladá fronta, a,s, Praha.
Guidelines of the National Centre for Treatment of Inherited Metabolic Diseases (Institute of Inherited Metabolic Disorders, Charles University–First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic. Available at http://udmp.lf1.cuni.cz/ (accessed 27 September 2016).
Spronsen JF, Wegberg MJA, Ahring K, Bélanger-Quintana A, Blau N, Bosch A et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 2017. Available at http://www.sciencedirect.com/science/article/pii/S2213858716303205.
Soltanizadeh N, Mirmoghtadaie L . Strategies used in production of phenylalanine-free foods for PKU management. Compr Rev Food Sci Food Saf 2014; 13: 287–299.
Exchange rates, cumulative averages. Czech National Bank. Available at http://www.cnb.cz/cs/financni_trhy/devizovy_trh/kurzy_devizoveho_trhu/prumerne_mena.jsp?mena=EUR (accessed 27 September 2016).
Trefz FK, Spronsen FJ, MacDonald A, Feillet F, Muntau CA, Belanger-Quintana A et al. Management of adult patients with phenylketonuria: survey results from 24 countries. Eur J Pediatr 2015; 174: 119–127.
Jahja R, Huijbregts SCJ, Sonneville LMJ, Meere JJ, Spronsen JF . Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr 2014; 164: 895–899.e2.
Trefz F, Maillot F, Motzfeldt K, Schwarz M . Adult phenylketonuria outcome and management. Mol Genet Metab 2011; 104: S26–S30.
Albrecht J, Gerbade SF, Burgard P . Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta analysis. Neurosci Biobehav Rev 2009; 33: 414–421.
Okano Y, Nagasaka H . Optimal serum phenylalanine for adult patients with phenylketonuria. Mol Genet Metab 2013; 110: 424–430.
Expenditure and household family statistics, Family Budget for the year 2015. Czech Statistical Office. Available at https://www.czso.cz/csu/czso/vydani-a-spotreba-domacnosti-statistiky-rodinnych-uctu-domacnosti-podle-postaveni-osoby-v-cele-podle-velikosti-obce-prijmova-pasma-regiony-soudrznosti-2015 (accessed 27 September 2016).
Peňa MJ, Almeida MF, Dam E, Ahring K, Belanger-Quintana A, Dokoupil K et al. Special low protein foods for phenylketonuria: availability in Europe and an examination of their nutritional profile. Orphanet J Rare Dis 2015; 10: 162.
Procházková D, Jarkovský J, Vinohradská H, Konečná P, Machačová L, Doležel Z . Fenylketonurie v dospělosti. Československá Pediatrie 2008; 63: 601–605.
Cotugno G, Nicoló R, Cappelletti S, Goffredo BM, Vici DC, Ciommo V . Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr 2011; 100: 1144–1149.
Ahring K, Bélanger-Quintana A, Dokoupil K, Ozel-Gokmen H, Lammardo AM, MacDonald A et al. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur J Clin Nutr 2011; 65: 275–278.
Bik-Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis 2008; 31 (Suppl 2): S415–S418.
Brown MCJ, Guest JF . Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria. J Intellect Disabil Res 1999; 43: 30–37.
Mlcoch T, Klimes J, Fila L, Vávrová V, Skalická V, Turnovec M et al. Cost-of-illness analysis and regression modelling in cystic fibrosis: a retrospective prevalence-based study. Eur J Health Econ 2017; 18: 73–82.
Acknowledgements
We would like to thank NSPKU and all study participants for their willing cooperation, without which this study would not have been possible, and to Květoslava Mlčochová MSc. for her thoughtful revision of our manuscript. Pavel Ješina received support from general grant RVO VFN 64165.
Author contributions
TM, RP, ŠŠ, ML and TD designed and conducted research, and created the questionnaire for patients. TM, RP and TD wrote the manuscript and TM had primary responsibility for final content. TM and RP analyzed the data and TM performed statistical analysis. ŠŠ, ML and PJ conducted repeated and throughout revisions of the manuscript. PJ wrote medical parts of the manuscript and was concerned with medical aspects of the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RP and ŠŠ are members of NSPKU and ML is a NSPKU volunteer. NSPKU receives sponsorship from several producers of food for special medical purposes, including low-protein food. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on European Journal of Clinical Nutrition website
Supplementary information
Rights and permissions
About this article
Cite this article
Mlčoch, T., Puda, R., Ješina, P. et al. Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases. Eur J Clin Nutr 72, 87–92 (2018). https://doi.org/10.1038/ejcn.2017.102
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2017.102